Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Pfizer |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00569725 |
To provide access to SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol. Because this is a continuation protocol for different studies, the population will consist of patients with different solid advanced malignancies treated with a variety of therapies including single agent SU011248 and in combination with chemotherapy, and placebo (patients who did not qualify for cross-over within the previous trial due to declining health status).
Condition | Intervention |
---|---|
Advanced Cancer Solid Tumors |
Drug: SU011248 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Treatment Protocol for Patients Continuing From SU011248 Protocols |
Estimated Enrollment: | 20 |
Study Start Date: | October 2007 |
Estimated Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
SU011248
|
Drug: SU011248
50 mg PO Daily
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion:
Contact: Christopher Logothetis, MD | 713-792-2830 |
United States, Texas | |
U.T.M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Christopher Logothetis, MD |
Principal Investigator: | Christopher Logothetis, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T.M.D. Anderson Cancer Center ( Christopher Logothetis, MD/Chair ) |
Study ID Numbers: | 2006-0877 |
Study First Received: | December 5, 2007 |
Last Updated: | March 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00569725 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Advanced Cancer Solid Tumors SU011248 Sunitinib |
Sunitinib Angiogenesis Inhibitors |
Antineoplastic Agents Sunitinib Growth Substances Therapeutic Uses Physiological Effects of Drugs |
Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions |